AUPHDoubtfulB
Unlock full report, free

Compliance Status

Doubtful

Screened on Oct 15, 2026 · AAOIFI Standard 21

B

Acceptable

69Score

Is Aurinia Pharmaceuticals Inc. (AUPH) halal? Doubtful. Based on AAOIFI screening, Aurinia Pharmaceuticals Inc. passes the business activity screen but has financial ratios approaching AAOIFI limits with a compliance score of 69/100 (Grade: B).

Quote this verdict

HalalScreener rates Aurinia Pharmaceuticals Inc. (AUPH) Doubtful, 69/100, grade B under AAOIFI Standard 21, screened Oct 15, 2026. Source: https://halalscreener.app/en/stock/AUPH

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

2.7% of 30.0% limit
PRO DETAIL

The verdict above is final and free.

Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.

Card needed, nothing charged today

Screened according to AAOIFI Standard 21

What this means for you

You may own AUPH, with caution

Its numbers sit close to AAOIFI limits. Cautious investors may prefer alternatives or ask a scholar first.

Purification amount is Pro

We have screened AUPH's prohibited income, but the exact share you would need to purify is part of Pro.

Card needed, nothing charged today
Aurinia Pharmaceuticals Inc.

AUPH: Is Aurinia Pharmaceuticals Inc. Halal?

Aurinia Pharmaceuticals Inc.

NASDAQHealthcareCA

$16.51

Market Cap: 2.2B

Get an email if AUPH's halal status changes

We re-screen Aurinia Pharmaceuticals Inc. daily. If the verdict moves, you hear about it the same day.

Free. One click sets it up, and you can unsubscribe any time.

About Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.

Sector: Healthcare · Industry: Biotechnology

Why This Stock Is Doubtful

  • Income from prohibited sources is close to the 5% limit.

Stocks are marked Doubtful when financial ratios pass but approach AAOIFI thresholds. Consider consulting a qualified scholar for a definitive ruling.

Shariah Compliance Status

AAOIFI Standard 21Updated Oct 15, 2026

See which ratio caused the failure.

See the exact debt ratio, interest income %, and prohibited revenue that caused the failure. Know before you sell or hold.

Free for 7 days. Cancel anytime.

Card needed, nothing charged today

AI Compliance Insight

PRO

Institutional-grade Shariah analysis

Card needed, nothing charged today

See why AUPH is rated Doubtful with institutional-grade analysis

PRO DETAIL

The verdict above is final and free.

Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.

Card needed, nothing charged today

Screened according to AAOIFI Standard 21

Compliance History

  1. Doubtfulnow

    since Aug 2026

  2. Halal

    until the change above

  3. Not Halal

    until the change above

  4. Halal

    until the change above

Tracked since May 2026. Updates automatically on each re-screen.

Fiscal: Q2 2026Data source: EDGAR
Free · No credit card required

Know the day AUPH's verdict changes

A free account keeps watch on 3 stocks and emails you when a verdict moves. You also get 3 questions for the AI Scholar. No card needed.

8,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Aurinia Pharmaceuticals Inc. (AUPH) halal to invest in?
Aurinia Pharmaceuticals Inc. (AUPH) is rated Doubtful under AAOIFI Standard 21. It passes the business activity screen but one or more financial ratios are approaching (though not yet exceeding) the AAOIFI thresholds (30% for debt and interest deposits, 5% for prohibited income). Consult a qualified Islamic finance scholar for a personal ruling.
Why did Aurinia Pharmaceuticals Inc. get a B compliance rating?
Aurinia Pharmaceuticals Inc. (AUPH) received a grade of B (Acceptable) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 2.7% (limit 30%). The grade reflects the margin of safety across all three ratios relative to their thresholds.
What could change Aurinia Pharmaceuticals Inc.'s Shariah verdict?
Aurinia Pharmaceuticals Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.
How often is Aurinia Pharmaceuticals Inc. re-screened for Shariah compliance?
Aurinia Pharmaceuticals Inc. (AUPH) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Oct 15, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.